Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
about
Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors TreatmentCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsA novel AHI-1-BCR-ABL-DNM2 complex regulates leukemic properties of primitive CML cells through enhanced cellular endocytosis and ROS-mediated autophagy.JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo.GFI1B, EVI5, MYB--additional genes that cooperate with the human BCL6 gene to promote the development of lymphomasEmerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignanciesAlternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression.A Subpopulation of the K562 Cells Are Killed by Curcumin Treatment after G2/M Arrest and Mitotic Catastrophe.Identification of novel small molecule inhibitors of centrosome clustering in cancer cellsCML cells actively evade host immune surveillance through cytokine-mediated downregulation of MHC-II expression.Preclinical approaches in chronic myeloid leukemia: from cells to systemsJAK inhibitors suppress t(8;21) fusion protein-induced leukemia.Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia.Mind the methyl: methyllysine binding proteins in epigenetic regulation.Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: importance of achieving treatment-free remission.Do we need more drugs for chronic myeloid leukemia?miR-101 sensitizes K562 cell line to imatinib through Jak2 downregulation and inhibition of NF-κB target genes.Current trends in molecular diagnostics of chronic myeloid leukemia.Cellular and Molecular Networks in Chronic Myeloid Leukemia: The Leukemic Stem, Progenitor and Stromal Cell Interplay.Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex.Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells.Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms.Targeting the JAK2-STAT5 pathway in CML.Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia.MS AHI1 genetic risk promotes IFNγ+ CD4+ T cells.Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia.The JAK2 blocker TG101209 is a potent inhibitor of clonogenic progenitor cell growth in patients with chronic myeloid leukaemia.BIN1 tumor suppressor regulates Fas/Fas ligand-mediated apoptosis through c-FLIP in cutaneous T-cell lymphoma.New Mouse Models to Investigate the Efficacy of Drug Combinations in Human Chronic Myeloid Leukemia.
P2860
Q26766299-72C00959-7906-4370-86EB-742B39C30629Q26778929-164BDFC6-DB5F-40A5-937B-2636DB8F13A0Q30008755-7F3B1B78-DA4C-4D62-AAF4-BF6E5E1D12EAQ34106870-6873C21B-971D-4B14-B8C5-2FD3B931A824Q34748896-861A1809-347E-4BB4-B767-CD25D4233DB8Q35132241-6AA7747F-DAD4-4749-B26E-A7A652A8CDF6Q35931271-02B963E6-0CC5-48D8-BAD2-5AAF8E82F784Q36080675-8BAB39AB-7954-4FAF-B3BC-660F6FAA14AEQ36188696-74D8CCBC-434D-401A-BE56-C95C3A65024DQ37381616-452F4031-6290-4BDB-8A92-46407012FB6EQ37638846-85C57CF1-44EA-42F4-B6BA-C141CA15A47BQ37676954-08318752-CA90-42B8-8AFD-07CD68F7A727Q37704373-C5BA1E24-D7E1-4592-8F78-87FD2C02F51AQ38175466-DEF5BFB9-E8B0-4C92-B18C-6D7B229C76BCQ38180674-A876DBBD-F693-4CD4-B018-AA2B76B68881Q38187388-D5C7D137-C9AB-4436-B9B2-8DDCFA6084EDQ38269617-0FC5949A-DB28-4231-8FBF-0241965CA3CCQ38289033-335E7E1E-0C62-4E2B-A378-157CDAAFACD8Q38752301-E164F373-55DB-410B-B9EF-23A2A60379A1Q38787015-C4CA7F0B-A448-4B91-B165-91D2D42C31E0Q38866390-806EA77B-0D5C-45C9-B42E-6635DC58194DQ41279430-437CDBCF-9F33-4914-94DB-39325300358EQ41807279-F88E9E83-5F8C-485F-B976-E135B4C5E4C6Q42551545-DEF69843-7612-4EBA-BA81-235F163CF3EDQ42737592-3391F98F-6584-4C21-B40D-88DAD5D0F88CQ47877771-42256254-92A1-480B-B77E-90ADABCDA965Q49422874-750FC08F-C333-44CC-BEE9-3D47C1E142A2Q49887884-89124130-45EB-43BE-86C4-1E95877F6FF0Q52788078-DD91994C-A2A6-4993-99C3-FBCC9CE19E24Q52976582-224D42F0-2CDB-4FD1-A0E7-08F586191E27Q55016655-6F84EC36-DF87-452E-ABF8-4F16C96D29A2
P2860
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@ast
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@en
type
label
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@ast
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@en
prefLabel
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@ast
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@en
P2093
P2860
P50
P356
P1476
Targeting primitive chronic my ...... ew AHI-1-BCR-ABL-JAK2 complex.
@en
P2093
Allen Eaves
Ashley Ringrose
Connie J Eaves
Damian Lai
Donna DeGeer
Donna L Forrest
Heather Jorgensen
Helen Nakamoto
Hui Mi Wang
James Paul
P2860
P304
P356
10.1093/JNCI/DJT006
P407
P577
2013-02-27T00:00:00Z